Access cutting-edge advanced solid tumors treatment through this phase 1 clinical trial at a research site in Grand Rapids. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Grand Rapids location
Preparing your pre-screening questions…
Access advanced solid tumors specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related advanced solid tumors treatment provided free
Check if you qualify for this advanced solid tumors clinical trial in Grand Rapids, MI
No-Cost Study Care
Local to Grand Rapids
Convenient for MI residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253. ABBV-253 is an investigational drug being developed for the treatment of advanced solid tumors. This open-label study consists of two parts. In Part 1 (ABBV-253 dose escalation), participants with any of the eligible cancer types will receive 1 of 4 (or more) doses of ABBV-253. Each cohort receives a higher dose, lower dose, or the same dose of ABBV-253 than the previous group. In Part 2 (ABBV-253 dose optimization), a new group of participants with NSCLC will be randomly put into pre-determined dose groups to receive 1 of 3 doses of ABBV-253. Approximately 130 participants will be enrolled in the study at approximately 11 sites worldwide. Participants will receive intravenous (IV) infusion of ABBV-253, as part of the 4 year study. There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Sponsor: AbbVie
Yes, this clinical trial (NCT07807956) has an active research site in Grand Rapids, MI that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for advanced solid tumors treatment options in Grand Rapids, MI, this clinical trial (NCT07807956) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Grand Rapids research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced advanced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all advanced solid tumors clinical trials near you to find additional studies recruiting in your area.
See all advanced solid tumors clinical trials recruiting in Grand Rapids — not just this study.
Browse Advanced Solid Tumors Trials in Grand Rapids →